June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Evaluation of the efficacy of rAAV2/2-ND4 gene therapy for Leber hereditary optic neuropathy compared with the natural history
Author Affiliations & Notes
  • Patrick Yu-Wai-Man
    University of Cambridge, Cambridge, Cambridgeshire, United Kingdom
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Nancy J Newman
    Emory University, Atlanta, Georgia, United States
  • Valerio Carelli
    Universita di Bologna, Bologna, Emilia-Romagna, Italy
  • Mark Moster
    Wills Eye Hospital, Philadelphia, Pennsylvania, United States
    Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, United States
  • Catherine Vignal-Clermont
    Rothschild Foundation Hospital, France
    Centre Hospitalier National d’Ophtalmologie des Quinze Vingts, France
  • Alfredo A Sadun
    Doheny Eye Institute, Los Angeles, California, United States
  • Chiara La Morgia
    Universita di Bologna, Bologna, Emilia-Romagna, Italy
  • Francesco Bandello
    IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Lorena Castillo Campillo
    Institut Catala de Retina SL, Barcelona, Catalunya, Spain
  • Stephanie Leruez
    Centre Hospitalier Universitaire d'Angers, Angers, Pays de la Loire, France
  • Dean Cestari
    Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
  • Robert Foroozan
    Baylor College of Medicine Department of Ophthalmology, Houston, Texas, United States
  • Rustum Karanjia
    Doheny Eye Institute, Los Angeles, California, United States
    University of Ottawa, Ottawa, Ontario, Canada
  • Laure Blouin
    GenSight Biologics SA, Paris, Île-de-France, France
  • Magali Taiel
    GenSight Biologics SA, Paris, Île-de-France, France
  • Jose Alain Sahel
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
    Institut de la vision, Paris, Île-de-France, France
  • Footnotes
    Commercial Relationships   Patrick Yu-Wai-Man, GenSight Biologics (C); Nancy Newman, GenSight Biologics (C); Valerio Carelli, GenSight Biologics (C); Mark Moster, GenSight Biologics (C); Catherine Vignal-Clermont, GenSight Biologics (C); Alfredo Sadun, None; Chiara La Morgia, None; Francesco Bandello, None; Lorena Castillo Campillo, None; Stephanie Leruez, None; Dean Cestari, None; Robert Foroozan, None; Rustum Karanjia, None; Laure Blouin, GenSight Biologics (E); Magali Taiel, GenSight Biologics (E); Jose Sahel, GenSight Biologics (I), GenSight Biologics (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2676. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Patrick Yu-Wai-Man, Nancy J Newman, Valerio Carelli, Mark Moster, Catherine Vignal-Clermont, Alfredo A Sadun, Chiara La Morgia, Francesco Bandello, Lorena Castillo Campillo, Stephanie Leruez, Dean Cestari, Robert Foroozan, Rustum Karanjia, Laure Blouin, Magali Taiel, Jose Alain Sahel; Evaluation of the efficacy of rAAV2/2-ND4 gene therapy for Leber hereditary optic neuropathy compared with the natural history. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2676.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Two Phase 3 multicenter clinical trials, RESCUE (NCT02652767) and REVERSE (NCT02652780), showed unexpected sustained bilateral improvement of best-corrected visual acuity (BCVA) following unilateral injection of rAAV2/2-ND4 gene therapy in patients with Leber hereditary optic neuropathy (LHON). In this study, we compared the treatment effect of rAAV2/2-ND4 with an external control group of untreated patients.

Methods : The treated population consisted of 76 ND4-LHON subjects injected unilaterally with rAAV2/2-ND4 in the RESCUE and REVERSE trials, of which 62 subjects enrolled in a long-term follow-up study (NCT03406104). The untreated population included a total of 208 subjects: 23 ND4-LHON subjects enrolled in the REALITY LHON Registry (NCT03295071) and 185 ND4-LHON subjects with individual patient-level data collected from 10 natural history studies in the literature. To allow for comparison with the treated population, the untreated population included only patients who were at least 15 years old at onset of vision loss. A Locally Estimated Scatterplot Smoothing (LOESS), non-parametric, local regression model was used to represent the evolution of BCVA over time. Comparison of BCVA between treated and untreated patients was performed at 12, 18, 24, 36 and 48 months after onset of vision loss.

Results : BCVA evolution in the treated patients showed gradual, progressive, and sustained improvement from Month 12 to the last available observation (on average 51.5 months), whereas no recovery was observed in the untreated patients. At Month 48, mean BCVA was 1.26 LogMAR for treated patients and 1.59 LogMAR for untreated patients, which is a difference of 0.33 LogMAR or 16.5 ETDRS letters equivalent (p<0.01 for Kruskal -Wallis and repeated measures tests).

Conclusions : This indirect comparison of 76 treated patients with an external control group of 208 untreated patients showed a clinically meaningful effect of gene therapy on visual outcomes in ND4-LHON patients.

This is a 2021 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.